Diagnosis of cardiac surgery-associated acute kidney injury : differential roles of creatinine, chitinase 3-like protein 1 and neutrophil gelatinase-associated lipocalin : a prospective cohort study by De Loor, Jorien et al.
De Loor et al. Ann. Intensive Care  (2017) 7:24 
DOI 10.1186/s13613-017-0251-z
RESEARCH 
Diagnosis of cardiac surgery-associated 
acute kidney injury: differential roles 
of creatinine, chitinase 3-like protein 1 
and neutrophil gelatinase-associated lipocalin: a 
prospective cohort study
Jorien De Loor1*, Ingrid Herck2, Katrien Francois3, Astrid Van Wesemael4, Lieve Nuytinck5, Evelyne Meyer1† 
and Eric A. J. Hoste2,6†
Abstract 
Background: A common and serious complication of cardiac surgery prompting early detection and intervention 
is cardiac surgery-associated acute kidney injury (CSA-AKI). Urinary chitinase 3-like protein 1 (UCHI3L1) was found to 
predict AKI associated with critical illness in adults. Our aims were therefore to evaluate whether UCHI3L1 can also be 
used to predict AKI associated with elective cardiac surgery in adults, and to compare this predictive ability with that 
of urinary neutrophil gelatinase-associated lipocalin (UNGAL), more frequently assessed early serum creatinine (SCr) 
measurements, and various two-biomarker panels.
Methods: This was a single-centre prospective cohort study at the eight-bed cardiac surgery ICU of Ghent University 
Hospital. AKI was diagnosed and classified according to the Kidney Disease|Improving Global Outcomes definitions 
for the diagnosis and staging of AKI, which are based on SCr and urine output (UO). Of the 211 enrolled elective 
cardiac surgery patients, we included 203 patients who had no AKI pre-operatively and at time of post-operative ICU 
admission (t1) in the primary endpoint analysis (i.e. AKI stage ≥1 within 48 h after t1), while 210 patients without AKI 
stage ≥2 pre-operatively and at t1 were included in the secondary endpoint analysis (i.e. AKI stage ≥2 within 12 h 
after t1). Systemic and/or urine concentrations of Cr, CHI3L1 and NGAL were measured more frequently than SCr in 
routine early post-operative ICU practice. UO was monitored hourly in the ICU.
Results: Within 48 h after t1, 46.8% of the patients had developed AKI (70.5% stage 1, 20.0% stage 2 and 9.5% stage 
3). In the early post-operative period, only SCr was a good predictor of AKI within 48 h after t1 (primary endpoint). 
SCHI3L1 combined with either UCHI3L1 or UNGAL was a good predictor of AKI stage ≥2 within 12 h after t1 (second-
ary endpoint). However, SCr and its absolute difference from pre-operative to early measures after surgery outper-
formed these combinations.
Conclusions: We found that more frequent assessment of the functional biomarker SCr in the early post-operative 
ICU period (first 4 h) after elective cardiac surgery in adult patients had good to excellent predictive value for CSA-AKI, 
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Background
Cardiac surgery-associated acute kidney injury (CSA-
AKI) is a common and serious complication of cardiac 
surgery [1]. Depending on its severity and differences in 
both baseline characteristics and type of cardiac surgical 
procedure, the range of incidence of CSA-AKI is between 
3.0 and 50.0% when applying Kidney Disease|Improving 
Global Outcomes (KDIGO)-like criteria [2–6]. CSA-AKI 
treated with renal replacement therapy (RRT) presents 
post-operatively in 2.0–6.0% of cardiac surgery patients 
[5, 7, 8], of which 1 out of 2 die in hospital [5]. Impor-
tantly, also when the injury is mild, CSA-AKI is inde-
pendently associated with significant effects on early [i.e. 
hospital or 30-day (d)] mortality [9, 10].
Risk for CSA-AKI is increased by the presence of estab-
lished pre-operative [e.g. increased serum creatinine 
(SCr)] and peri-operative (e.g. low cardiac output) factors 
that increase susceptibility to AKI [11, 12]. Moreover, 
potentially important modifiable intra-operative suscep-
tibilities are the type of cardiac surgical technique and, if 
cardiopulmonary bypass [CPB; synonym: extracorporeal 
circulation (ECC)] is used, the characteristics of the per-
fusion technique [13]. Early CSA-AKI occurs within 7 d 
after the cardiac surgical procedure and is directly related 
to it [14]. CSA-AKI more than 1  week but within 30 d 
after the cardiac surgical procedure is mainly related to 
another exposure that presents as a complication of the 
cardiac surgical procedure (e.g. sepsis) [14].
Only recently the term ‘acute kidney stress’ (AKS) was 
proposed to describe the pre-injury phase that leads to 
AKI [15]. Biomarkers, or ‘measurable and quantifiable 
biological parameters’ [16], that respond to AKS open 
new horizons in regard to the prediction and early detec-
tion of emerging AKI. These biomarkers serve as surrogate 
measurements, estimating renal cell perfusion, function 
or metabolism [15]. As regulator of the iron metabolism, 
neutrophil gelatinase-associated lipocalin (NGAL) meas-
ured in blood or urine represents a way to monitor initial 
damage [17], which was confirmed in more than 7000 pae-
diatric and adult patients who underwent cardiac surgery 
[18–20]. Recently, our group demonstrated the role of uri-
nary chitinase 3-like protein 1 (UCHI3L1) as predictor of 
AKI in an adult general intensive care unit (ICU) cohort, 
with a performance similar to that of UNGAL [21].
Higher systemic concentrations of CHI3L1 have been 
independently associated with the presence of coronary 
artery disease, seeming a quantitative indicator of dis-
ease progression as well [22]. Additionally, it was shown 
that in patients with type 1 and type 2 diabetes mellitus 
higher systemic concentrations of CHI3L1 were associ-
ated with progressing vascular damage in the kidneys, 
as assessed by the level of albuminuria [22]. It seems 
plausible that low-grade inflammation and endothelial 
dysfunction progressing to micro- and macrovascular 
complications account for higher systemic concentra-
tions of CHI3L1. Besides a marker of chronic inflamma-
tion, systemic CHI3L1 is a marker of acute inflammation 
as well [23]. Cardiac surgery and the use of CPB have 
a critical role in inducing the systemic inflammatory 
response syndrome leading to CSA-AKI. Consequently, 
SCHI3L1 can be proposed as a potential AKI risk factor.
The objectives of this study were:
(a) To evaluate whether UCHI3L1 can be used to pre-
dict occurrence of AKI in adult patients who under-
went elective cardiac surgery,
(b) To compare this predictive ability with that of 
UNGAL, a well-known biomarker of tubular dam-
age, and that of more frequently assessed early 
measurements of SCr, a routine biomarker of kid-
ney dysfunction,
(c) To evaluate whether combining either two urinary 
renal stress or damage biomarkers, or a systemic 
kidney dysfunction biomarker and a urinary renal 
stress or damage biomarker can improve the pre-
dictive ability for CSA-AKI,
(d) To evaluate whether combining SCHI3L1 with 
either a systemic kidney dysfunction biomarker 
or a urinary renal stress or damage biomarker can 
improve the predictive ability for CSA-AKI.
Methods
This research is reported according to the STrengthening 
the Reporting of OBservational studies in Epidemiology 
(STROBE) Statement (Additional file 1: Fig. S1) [24].
Defining AKI
AKI was diagnosed and classified according to the 
KDIGO definitions for the diagnosis and staging of AKI, 
which are based on SCr and urine output (UO) (Addi-
tional file 2: Fig. S2) [25].
indicating that routine SCr assessment must become more frequent in order to detect AKI more early. This perfor-
mance was in contrast with the inadequate predictive value of the urinary renal stress or damage biomarkers UCHI3L1 
and UNGAL.
Keywords: Acute kidney injury, Biological markers, Chitinase, Cardiac surgery, Lipocalins
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Study patients
In this single-centre cohort study, we prospectively 
enrolled patients who were admitted to the eight-bed 
cardiac surgery ICU of Ghent University Hospital from 
May 2012 till February 2014. The inclusion and exclusion 
criteria of the study are incorporated in the flow diagram 
in Fig. 1.
Primary endpoint
The primary endpoint of the current study was the devel-
opment of AKI stage ≥1 within 48 h after t1. Reference 
SCr, representing baseline SCr, was defined as the lowest 
SCr value within the last 3 months (mo) prior to enrol-
ment (lowest of history SCr value(s) and pre-operative 
SCr). In our cohort 30.0% of the patients had only the 
pre-operative SCr value available. In 49.3% the lowest 
history SCr was lower than or equal to the pre-operative 
SCr, while in 20.7% the pre-operative SCr was lower than 
the lowest history SCr. The details for calculation of UO 
are outlined by our group [21]. Note that UO was regis-
tered hourly in the ICU only.
Secondary endpoint
The secondary endpoint was AKI stage ≥2 within 12  h 
after t1.
Ethics approval and consent to participate
The Ethical Committee of Ghent University Hospital 
approved this study (Belgian Registration Number of 
the study: B670201213147). All patients or their legally 
authorized representatives provided written informed 
consent. We respected the Declaration of Helsinki and 
the Good Clinical Practice Guidelines.
Prospective sample and data collection
The first collection of blood and urine was after the 
induction of anaesthesia and before the start of surgery 
[time 0 (t0) on the day of surgery (dsurgery)]. The rest of 
the specimens (n  =  7) were collected post-operatively, 
starting at ICU admission (t1) and then at 2 hours (h) 
(t2), 4 h (t3), 6 h, 12 h, 24 h and 48 h after ICU admission. 
If the patient was discharged to the Midcare unit before 
24 h or 48 h, those samples were collected there. When-
ever possible, the routine collection times were followed 
[at 4 PM on the first post-operative day (d1post-op) and at 
6 AM on the second post-operative day (d2post-op)]. The 
sample collection times for a fictional patient who under-
went surgery in the morning are outlined on the timeline 
in Additional file  3: Fig. S3A, while those for a fictional 
patient who underwent surgery in the afternoon are out-
lined on the timeline in Additional file 4: Fig. S3B.
These paired blood and urine samples were collected by 
standard methods and centrifuged by standard protocols, 
as described previously by our group [21]. Serum and 
urine supernatants were stored at −80 °C and thawed at 
room temperature immediately prior to analysis. Clinical 
data needed to complete the individual clinical research 
files (Additional file 5: Table S1) were extracted from the 
hospital records by study coordinators. Note that Addi-
tional file 5 contains Tables S1, S2, S3, S4A, B, C, D and 
the legends of Figures S1, S2, S3A, B, S4, S5, S6. Samples 
were anonymized as were clinical data. All technicians 
were blinded to clinical data.
Biomarker analysis and single‑biomarker diagnostic test 
possibilities
The CHI3L1 analysis was performed in-house. We 
measured the concentration of CHI3L1 by a sandwich 
enzyme-linked immunosorbent assay (ELISA) tech-
nique (DC3L10, R&D Systems, Minneapolis, MN, USA). 
Analyses performed externally were Cr and UNGAL. 
The Cobas c502 measured the concentration of Cr by a 
kinetic rate-blanked Jaffé assay (commercial reagents, 
Roche Diagnostics, Basel, Switzerland), whereas the 
Modular P measured the concentration of UNGAL by a 
particle-enhanced turbidimetric immunoassay (ST001-
3CA, BioPorto, Hellerup, Denmark). All details were 
recently described [21], except for the standard sample 
dilution scheme used in the CHI3L1 ELISA, which is pre-
sented in Additional file  5: Table S2. For blood samples 
that were collected at routine collection times, a SCr con-
centration was already available in the hospital records. 
Based on the temporal relationship of the predictive 
value of UNGAL for CSA-AKI [19], we measured this 
biomarker at t1 and t3 only.
Besides UCHI3L1 and UNGAL, we also evaluated 
UCHI3L1 and UNGAL corrected for urine dilution by 
using the ratio to UCr as diagnostic test. Besides SCr, we 
also evaluated ΔSCrtx-t0 as diagnostic test, representing 
the absolute change in SCr between SCrtx and SCrt0. The 
most recent SCr value recorded prior to surgery was con-
sidered as SCrt0.
Defining acute tubular damage and subclinical AKI
Following the recommendations of de Geus et al., acute 
tubular damage was defined as a CSA-NGAL score of 2 
or greater; either as UNGALt1 or UNGALt3 ≥ 150 ng/ml 
or as ∆UNGALt3-t1 > 100 ng/ml with UNGALt3 ≥ 125 ng/
ml [26]. Subclinical AKI was defined when there was 
acute tubular damage (according to the ‘de Geus criteria’) 
and absence of AKI according to the KDIGO definition.
Defining good and excellent biomarkers
An area under the receiver operating characteristics 
curve (AUC-ROC) of 0.750 or greater was considered to 
represent a good biomarker, whereas an AUC-ROC of 
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No. of adults (≥ 18 y) admitted to
the post-operative cardiac surgery ICU
from May 2012 till February 2014
N = 1064
Enrolled
N = 211
Analysed
N = 203
AKI stage ≥ 1 
at enrolment or 
at ICU admission
N = 8
Excluded
24-h window 48-h window
Primary endpoint
12-h window
No AKI
N = 157
77.3 %
No AKI
N = 118
58.1 %
No AKI
N = 108
53.2 %
7-d window
No AKI
N = 103
50.7 %
Inclusion criteria
►Elective surgerya
►Written informed consent
Exclusion criteria
►AKI stage ≥ 1b at time of enrolment
►CKD stage 5c
►Recent kidney transplantd
►Surgery on Sat or Sun
AKI stage 1
N = 43
21.2 %
Within 
AKI
93.5 %
AKI stage 2
N = 3
1.5 %
Within 
AKI
6.5 %
AKI stage 3
N = 0
0.0 %
Within 
AKI
0.0 %
AKI stage 1
N = 72
35.5 %
Within 
AKI
84.7 %
AKI stage 2
N = 12
5.9 %
Within 
AKI
14.1 %
AKI stage 3
N = 1
0.5 %
Within 
AKI
1.2 %
AKI stage 1
N = 67
33.0 %
Within 
AKI
70.5 %
AKI stage 2
N = 19
9.4 %
Within 
AKI
20.0 %
AKI stage 3
N = 9
4.4 %
Within 
AKI
9.5 %
AKI stage 1
N = 65
32.0 %
Within 
AKI
65.0 %
AKI stage 2
N = 21
10.3 %
Within 
AKI
21.0 %
AKI stage 3
N = 14
6.9 %
Within 
AKI
14.0 %
Fig. 1 Flow diagram of patient enrolment and primary endpoint analysis. aPlanned ≥4 h in advance. bKDIGO definitions for the diagnosis and 
staging of AKI, which are based on SCr and UO [25]. cKDOQI definitions for the diagnosis and staging of CKD [40]. d≤3 mo before. AKI acute kidney 
injury, CKD chronic kidney disease, d day, h hour, ICU intensive care unit, KDIGO Kidney Disease|Improving Global Outcomes, KDOQI Kidney Disease 
Outcomes Quality Initiative, mo month, No. number, Sat Saturday, SCr serum creatinine, Sun Sunday, UO urine output, y year
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0.900 or greater was considered to represent an excellent 
biomarker [27].
Statistical analysis
The principal statistical analysis was based on com-
parison of the AUC-ROCs of UCHI3L1 with those of 
UNGAL, more frequently assessed early measurements 
of SCr, and various two-biomarker panels for predict-
ing both defined endpoints. It was performed in Med-
Calc 15.2.1 (MedCalc Software, Oostende, Belgium). The 
unpaired comparison of a variable between two inde-
pendent samples was done in SPSS 22 (IBM, Armonk, 
NY, USA). Categorical variables were analysed with 
Fisher’s exact or the Chi-square test, and continuous 
variables with the nonparametric Mann–Whitney U test. 
Additionally, we calculated the 95% confidence interval 
(CI) for a proportion using the Wilson procedure with-
out a correction for continuity [28, 29]. For all analyses, 
two-sided P values <0.05 were considered statistically 
significant. All details and a description of how the bio-
markers were introduced into the statistical programs are 
provided in our previous work [21].
Results
Incidence of the primary endpoint, characteristics of the 
patients and procedures, and short‑term patient outcomes
The flow of patients during the study is illustrated in Fig. 1. 
The initial enrolment cohort consisted of 211 patients. In 
the primary endpoint analysis, 8 patients who already had 
AKI stage ≥1 at t0 (n =  3) or t1 were excluded, result-
ing in a total number of 203 patients for analysis. Within 
48 h after t1, 95 patients (46.8%) had developed AKI: 67 
(70.5%) were classified as stage 1, 19 (20.0%) as stage 2 and 
9 (9.5%) as stage 3. Three patients received RRT starting 
on d2post-op. Duration of RRT was 3  d in 2 patients and 
14 d in 1 patient. The flow of patients over different diag-
nostic windows for AKI is illustrated in Fig. 1. The limited 
extent to which the UO criterion identified AKI patients 
is illustrated in Additional file 6: Fig. S4. Median time to 
AKI diagnosis was 12.2 h [interquartile range (IQR) 7.2–
18.4  h]. Subclinical AKI, which was missed by KDIGO, 
occurred in 5.1% of the patients (Fig. 2).
Table 1 summarizes the characteristics of the patients 
and procedures at baseline. Compared with patients 
without AKI, patients who developed AKI within 48  h 
after t1 were older; had a higher body mass index (BMI); 
a lower eGFR; a higher prevalence of diabetes melli-
tus (DM) type 2; a higher predicted operative mortality, 
which was estimated by the simple additive European 
system for cardiac operative risk evaluation (Euro-
SCORE); more combined surgical procedures; and a 
higher prevalence of diuretic treatment at home.
Peri-operative characteristics of the patients and pro-
cedures are provided in Additional file  5: Table S3. In 
comparison with patients without AKI, patients who 
developed AKI within 48 h after t1 had a higher Sepsis-
related Organ Failure Assessment (SOFA) score; a higher 
white blood cell (WBC) count; a higher serum C-reactive 
protein (CRP) concentration; a more positive fluid bal-
ance; a higher number of plasma units that were trans-
fused; and a higher prevalence of vasopressor, milrinone 
and diuretic treatment.
AKI patients had a longer ICU and hospital length of 
stay (LOS) (Table 1).
Incidence of the secondary endpoint
In the secondary endpoint analysis, 1 patient who already 
had AKI stage ≥2 at t0 was excluded, resulting in a total 
number of 210 patients for analysis. Within 12  h after 
t1, 5 patients (2.4%) had developed AKI stage ≥2: all 
5 (100%) were classified as stage 2. The flow of patients 
over different diagnostic windows for AKI stage ≥2 is 
illustrated in Additional file 7: Fig. S5.
Biomarker performances for prediction of the primary 
endpoint
In the early post-operative period, only the functional 
biomarker SCr was a good predictor of AKI within 48 h 
after t1, showing the highest AUC-ROC at t3 (0.792; 
95% CI 0.728–0.847; Fig.  3). The information in Fig.  3 
is summarized in numerical format in Additional file  5: 
Tables S4B, C and D, including also the performances of 
the urinary renal stress or damage biomarkers corrected 
for urine dilution by using the ratio to UCr. Table S4A 
reports the performances of the biomarkers measured at 
t0.
Biomarker performances for prediction of the secondary 
endpoint
In the early post-operative period, SCHI3L1 combined 
with a urinary renal stress or damage biomarker, either 
UCHI3L1 or UNGAL, was a good predictor of AKI stage 
≥2 within 12 h after t1, showing the highest AUC-ROC at 
t2 when combined with UCHI3L1 (0.773; 95% CI 0.708–
0.829) and at t3 when combined with UNGAL (0.774; 
95% CI 0.710–0.830). However, the functional biomark-
ers SCr and ΔSCrtx-t0 outperformed these combinations 
with good to excellent performances, showing the high-
est AUC-ROC at t3 (0.857 for SCr; 95% CI 0.801–0.902; 
0.938 for ΔSCrtx−t0; 95% CI 0.860–1.000; Fig.  3). The 
information in Fig. 3 is summarized in numerical format 
in Additional file 5: Tables S4B, C and D, including also 
the performances of the urinary renal stress or damage 
biomarkers corrected for urine dilution by using the ratio 
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to UCr. Table S4A reports the performances of the bio-
markers measured at t0.
Discussion
We found that in adult patients who underwent elective 
cardiac surgery, UCHI3L1 had inadequate predictive 
value for CSA-AKI. This was also true for the well-known 
tubular damage biomarker UNGAL. In contrast, more 
frequent assessment of the functional biomarker SCr in 
the early post-operative ICU period (first 4 h) had good 
to excellent predictive value for CSA-AKI.
Similar to others, our ICU routinely measures SCr at t1 
and either around t4 (morning patient) or t5 (afternoon 
patient) in the early post-operative period. However, 
with ±50% of AKI diagnosed before t5, of which ±50% 
before t4, our study highlights the importance of more 
frequent SCr assessment in the first 4 h. This aids in early 
AKI diagnosis and could also reveal some cases of rapid 
reversal of AKI (i.e. ‘complete reversal of AKI by KDIGO 
criteria within 48 h of AKI onset’ [30]). These findings are 
in accordance with those of a small retrospective study 
(n = 29) by Maciel et al. [31].
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7.1 %
KDIGO
Stage 1 – 50.0 %
Stage 2 – 35.7 %
Stage 3 – 14.3 %
No AKI and no acute tubular 
damage
N = 96
48.7 %
KDIGO
No AKI – 100 %
AKI without acute tubular 
damage
N = 77
39.1 %
KDIGO
Stage 1 – 74.0 %
Stage 2 – 18.2 %
Stage 3 – 7.8 %
Subclinical AKI
N = 10
5.1 %
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N = 197
Fig. 2 Combining functional and damage biomarkers simultaneously to delineate the spectrum of AKI. Patients of the primary analysis cohort 
(n = 203) who had no UNGALt1 or UNGALt3 concentration available were excluded. Missing UNGALt1 occurred in 5 patients, and missing UNGALt3 
in 1 patient, resulting in a total of 197 patients. Following the recommendations of de Geus et al., acute tubular damage was defined as a CSA-NGAL 
score of 2 or greater; either as UNGALt1 or UNGALt3 ≥ 150 ng/ml or as ∆UNGALt3−t1 > 100 ng/ml with UNGALt3 ≥ 125 ng/ml [26]. Subclinical AKI 
was defined when there was acute tubular damage (according to the ‘de Geus criteria’) and absence of AKI according to the KDIGO definition. In 
this way 84.6% of AKI in our specific cohort (i.e. 77/[77 + 14]) was classified as AKI without acute tubular damage. Subclinical AKI, which was missed 
by KDIGO, occurred in 5.1% of the patients. AKI acute kidney injury, CSA cardiac surgery-associated, d day, KDIGO Kidney Disease|Improving Global 
Outcomes, t1 time of intensive care unit admission, t3 4 h after intensive care unit admission, UNGAL urinary neutrophil gelatinase-associated 
lipocalin
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Table 1 Characteristics of the patients and procedures at baseline, as well as short-term patient outcomes
No. (%)
[95% CI]
All patients
203 (100)
[98.1–100]
AKI stage ≥1a within 48 h
95 (46.8)
[40.1–53.7]
No AKIa within 48 h
108 (53.2)
[46.3–59.9]
P value
Characteristic
Male sex—no. (%) [95% CI] 133 (65.5)
[58.7–71.7]
65 (68.4)
[58.5–76.9]
68 (63.0)
[53.6–71.5]
0.461
White race—no. (%) [95% CI] 202 (99.5)
[97.3–99.9]
95 (100)
[96.1–100]
107 (99.1)
[94.9–99.8]
1.000
Ageb (IQR)—years 70.0 (61.0–76.0) 74.0 (65.0–80.0) 67.0 (58.0–75.0) <0.001
BMI (IQR) 27 (24–29) 27 (25–31) 26 (23–29) 0.004
Medical history
Reference renal function (IQR)
 SCr—mg/dl 0.90 (0.75–1.05) 0.99 (0.81–1.16) 0.82 (0.70–0.95) <0.001
 eGFRCKD-EPI—ml/min/1.73 m
2 82 (64–94) 73 (54–85) 87 (77–97) <0.001
DM—no. (%) [95% CI] 0.025
 Type 1 2 (1.0)
[0.3–3.5]
2 (2.1)
[0.6–7.4]
0 (0.0)
[0.0–3.4]
 Type 2 46 (22.7)
[17.4–28.9]
28 (29.5)
[21.2–39.3]
18 (16.7)
[10.8–24.8]
 No DM 155 (76.4)
[70.1–81.7]
65 (68.4)
[58.5–76.9]
90 (83.3)
[75.2–89.2]
Heart failure—no. (%) [95% CI] 0.252
 NYHA class I 145 (71.4)
[64.9–77.2]
64 (67.4)
[57.4–76.0]
81 (75.0)
[66.1–82.2]
 NYHA class II 36 (17.7)
[13.1–23.6]
17 (17.9)
[11.5–26.8]
19 (17.6)
[11.6–25.8]
 NYHA class III 20 (9.9)
[6.5–14.7]
12 (12.6)
[7.4–20.8]
8 (7.4)
[3.8–13.9]
 NYHA class IV 2 (1.0)
[0.3–3.5]
2 (2.1)
[0.6–7.4]
0 (0.0)
[0.0–3.4]
Clinical examination
Blood pressure (IQR)—mm Hg
 Systolic 134 (122–149) 132 (122–150) 134 (120–149) 0.704
 Diastolic 72 (64–78) 72 (63–78) 71 (66–78) 0.619
 Mean 93 (85–101) 92 (84–102) 93 (86–100) 0.734
Heart rhythm—no. (%) [95% CI] 0.074
 Atrial fibrillation 16 (7.9)
[4.9–12.4]
11 (11.6)
[6.6–19.6]
5 (4.6)
[2.0–10.4]
 Normal sinus rhythm 187 (92.1)
[87.6–95.1]
84 (88.4)
[80.4–93.4]
103 (95.4)
[89.6–98.0]
 Heart rate in normal sinus rhythm (IQR)—bpm
(N = 187)
69 (61–79) 70 (62–81) 69 (60–76) 0.143
Distribution of ejection fraction—no. (%) [95% CI] 0.531
 ≤20% 5 (2.5)
[1.1–5.6]
4 (4.2)
[1.6–10.3]
1 (0.9)
[0.2–5.1]
 21–30% 3 (1.5)
[0.5–4.3]
2 (2.1)
[0.6–7.4]
1 (0.9)
[0.2–5.1]
 31–50% 33 (16.3)
[11.8–22.0]
16 (16.8)
[10.6–25.6]
17 (15.7)
[10.1–23.8]
 >50% 119 (58.6)
[51.7–65.2]
55 (57.9)
[47.8–67.3]
64 (59.3)
[49.8–68.1]
Index surgical procedure
EuroSCORE (IQR) 5 (3–8) 6 (4–9) 5 (2–7) 0.004
Type of cardiac surgical procedure—no. (%) [95% CI] 0.005
 Isolated CABG 93 (45.8)
[39.1–52.7]
34 (35.8)
[26.9–45.8]
59 (54.6)
[45.2–63.7]
 Isolated valve repair or replacement 55 (27.1)
[21.4–33.6]
28 (29.5)
[21.2–39.3]
27 (25.0)
[17.8–33.9]
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ACE angiotensin-converting enzyme, AKI acute kidney injury, ARB angiotensin-II receptor blocker, BMI body mass index, bpm beats per minute, CABG coronary artery 
bypass grafting, CI confidence interval, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, DM diabetes mellitus, ECC extracorporeal circulation, eGFR 
estimated glomerular filtration rate, EuroSCORE European system for cardiac operative risk evaluation, h hour, IABP intra-aortic balloon pump, ICU intensive care unit, 
IQR interquartile range, KDIGO Kidney Disease|Improving Global Outcomes, LOS length of stay, min minute, no. number, NSAID nonsteroidal anti-inflammatory drug, 
NYHA New York Heart Association, RRT renal replacement therapy, SCr serum creatinine, UO urine output
a KDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO
b Determined at the day of surgery
Table 1 continued
No. (%)
[95% CI]
All patients
203 (100)
[98.1–100]
AKI stage ≥1a within 48 h
95 (46.8)
[40.1–53.7]
No AKIa within 48 h
108 (53.2)
[46.3–59.9]
P value
 CABG and valve repair or replacement 34 (16.7)
[12.2–22.5]
25 (26.3)
[18.5–36.0]
9 (8.3)
[4.4–15.1]
 Aortic root 12 (5.9)
[3.4–10.0]
5 (5.3)
[2.3–11.7]
7 (6.5)
[3.2–12.8]
 Other 9 (4.4)
[2.3–8.2]
3 (3.2)
[1.1–8.9]
6 (5.6)
[2.6–11.6]
ECC—no. (%) [95% CI] 0.516
 Yes 179 (88.2)
[83.0–91.9]
82 (86.3)
[78.0–91.8]
97 (89.8)
[82.7–94.2]
 No 24 (11.8)
[8.1–17.0]
13 (13.7)
[8.2–22.0]
11 (10.2)
[5.8–17.3]
 Duration of ECC (IQR)—min
N = 179
91.5 (70.8–123.3) 92.0 (70.3–131.3) 91.5 (70.3–117.8) 0.527
 Priming volume of ECC pump (IQR)—ml
N = 179
1300 (1200–1500) 1300 (1200–1500) 1300 (1150–1400) 0.246
 Duration of aortic clamp during ECC (IQR)—min
N = 179
56.0 (42.8–82.0) 62.0 (45.0–88.0) 55.0 (40.5–74.5) 0.174
 Duration of ischaemia during ECC (IQR)—min
N = 179
54.0 (39.0–78.0) 61.0 (43.0–81.0) 52.0 (37.8–70.5) 0.164
 Duration of surgery (IQR)—h 4.6 (3.9–5.2) 4.7 (3.9–5.3) 4.5 (3.9–5.1) 0.196
 IABP peri-operatively—no. (%) [95% CI] 7 (3.4)
[1.7–6.9]
2 (2.1)
[0.6–7.4]
5 (4.6)
[2.0–10.4]
0.452
Medication—no. (%) [95% CI]
Statins 127 (62.6)
[55.7–68.9]
63 (66.3)
[56.3–75.0]
64 (59.3)
[49.8–68.1]
0.313
ACE inhibitors 56 (27.6)
[21.9–34.1]
28 (29.5)
[21.2–39.3]
28 (25.9)
[18.6–34.9]
0.638
ARBs 7 (3.4)
[1.7–6.9]
6 (6.3)
[2.9–13.1]
1 (0.9)
[0.2–5.1]
0.052
Diuretics 51 (25.1)
[19.7–31.5]
36 (37.9)
[28.8–47.9]
15 (13.9)
[8.6–21.7]
<0.001
NSAIDs 4 (2.0)
[0.8–5.0]
1 (1.1)
[0.2–5.7]
3 (2.8)
[0.9–7.9]
0.624
Corticosteroids 13 (6.4)
[3.8–10.6]
8 (8.4)
[4.3–15.7]
5 (4.6)
[2.0–10.4]
0.390
Tacrolimus 0 (0.0)
[0.0–1.9]
0 (0.0)
[0.0–3.9]
0 (0.0)
[0.0–3.4]
NA
Cyclosporine 2 (1.0)
[0.3–3.5]
2 (2.1)
[0.6–7.4]
0 (0.0)
[0.0–3.4]
0.218
Aminoglycosides 3 (1.5)
[0.5–4.3]
1 (1.1)
[0.2–5.7]
2 (1.9)
[0.5–6.5]
1.000
Corticosteroids intra-operatively 0 (0.0)
[0.0–1.9]
0 (0.0)
[0.0–3.9]
0 (0.0)
[0.0–3.4]
NA
Iodinated contrast ≤72 h before surgery 37 (18.2)
[13.5–24.1]
14 (14.7)
[9.0–23.2]
23 (21.3)
[14.6–29.9]
0.275
Outcomes
RRT in ICU—no. (%) [95% CI] 3 (1.5)
[0.5–4.3]
3 (3.2)
[1.1–8.9]
0 (0.0)
[0.0–3.4]
0.101
ICU LOS (IQR)—d 1 (1–3) 2 (1–3) 1 (1–2) <0.001
Hospital LOS (IQR)—d 12 (9–16) 13 (10–20) 10 (9–13) <0.001
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Novel findings of our study are the good to excellent 
performances of ΔSCrt1−t0, ΔSCrt2−t0 and ΔSCrt3−t0 for 
the prediction of AKI stage ≥2 within 12  h after t1. In 
accordance with these results, measurement of very early 
post-operative SCr changes, either absolute [10] or rela-
tive [32, 33], in adult [10, 33] and paediatric [32] cardiac 
surgery patients has been reported to provide prognos-
tic utility for a subsequent diagnosis of AKI. However, 
each of these three studies was restricted by some of the 
following limitations: AKI was not defined according 
to KDIGO, including oliguric criteria; more severe AKI 
was not included as endpoint; SCr was less frequently 
assessed in the early post-operative period; and AUC-
ROC analysis was not reported.
The simultaneous utilization of functional and dam-
age biomarkers, as in the CSA-NGAL score [26], per-
mits to delineate the spectrum of AKI [34]. In this way 
84.6% of AKI in our specific cohort (i.e. 77/[77 +  14]) 
was classified as AKI without acute tubular damage. 
The capacity of the kidneys to increase baseline GFR 
under physiological or pathological kidney stress is 
described by the renal functional reserve of the glo-
merular function (Additional file  8: Fig. S6) [35]. In 
congestive heart failure, CKD and AKI, utilization of 
the renal functional reserve of the glomerular function 
allows to replace (in part) the lost function, maintaining 
a normal whole-organ baseline GFR until ±50% of the 
nephrons are nonfunctional. The presence of an intact 
renal functional reserve of the glomerular function and 
nephron mass guarantees a low renal frailty or suscep-
tibility [36]. Compared with the general ICU cohort of 
our previous AKI biomarker study [21], the patients 
in this study were older (median 70.0 vs. 60.0  y), more 
often diabetic (median 23.6 vs. 7.2%), had a higher BMI 
(median 27 vs. 24) and a lower baseline eGFR (median 
82 vs. 102  ml/min/1.73  m2). We therefore hypothesize 
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Fig. 3 Biomarker performances for prediction of AKI. Blue boxes correspond with the primary endpoint (i.e. AKI stage ≥1 within 48 h after t1), 
orange boxes with the secondary endpoint (i.e. AKI stage ≥2 within 12 h after t1). ΔSCr represents ΔSCrtx-t0, which is the absolute change in SCr 
between SCrtx and SCrt0. Biomarkers were measured a at ICU admission (t1), b 2 h after ICU admission (t2) and c 4 h after ICU admission (t3). AKI 
acute kidney injury, h hour, ICU intensive care unit, SCHI3L1 serum chitinase 3-like protein 1, SCr serum creatinine, UCHI3L1 urinary chitinase 3-like 
protein 1, UNGAL urinary neutrophil gelatinase-associated lipocalin
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that a lower renal functional reserve of the glomerular 
function and nephron mass in this population caused 
the low incidence of both subclinical AKI and AKI with 
acute tubular damage. This can also explain the inad-
equate performance of the urinary renal stress or dam-
age biomarkers UCHI3L1 and UNGAL for prediction of 
AKI stage ≥2 within 12 h after t1. Our study is, however, 
not the first to report inadequate diagnostic ability of 
UNGAL for moderate to severe CSA-AKI [20]. In their 
multicentre high-risk cohort with 21% emergent surger-
ies, 42% diabetic patients and a baseline eGFR of 67 ml/
min/1.73  m2, Parikh et  al. reported an AUC-ROC of 
0.67 (standard error (SE) 0.04) for the prediction of AKI 
defined by receipt of RRT or doubling of SCr [37]. Inter-
estingly, Koyner et al. found an AUC-ROC of 0.88 (95% 
CI 0.73–0.99) for the prediction of AKI Acute Kidney 
Injury Network (AKIN) stage 3 in a cohort comparable 
to ours [38], indicating the importance of the severity of 
AKI in the predictive ability of UNGAL.
Our study has several limitations. First, it is limited in 
being a single-centre study in elective cardiac surgery 
patients. However, baseline characteristics and the inci-
dence of AKI suggest that our population is representa-
tive of cardiac surgery ICUs in developed countries. 
Second, our study is further limited by the relatively 
low incidence of AKI stage ≥2 within 12 h after t1 (sec-
ondary endpoint). Both the fact that we included only 
elective surgeries and the implemented narrow diag-
nostic window contribute to this constraint. As such, 
these biomarker data need to be further validated in 
larger multicentre prospective studies. Third, we did not 
measure the panel of G1 cell-cycle arrest biomarkers 
tissue inhibitor of metalloproteinases 2 (TIMP-2) and 
insulin-like growth factor-binding protein 7 (IGFBP7) 
[39], because it was not available at the start of our 
study.
Conclusions
In summary, we demonstrated that more frequent assess-
ment of the functional biomarker SCr in the early post-
operative ICU period (first 4  h) after elective cardiac 
surgery in adult patients had good to excellent predictive 
value for CSA-AKI, indicating that routine SCr assess-
ment must become more frequent in order to detect AKI 
more early. We found that AKI was predominantly with-
out acute tubular damage and that subclinical AKI was 
uncommon in this cohort. This may explain the inad-
equate predictive value for CSA-AKI of the urinary renal 
stress or damage biomarkers UCHI3L1 and UNGAL. 
These results need to be further validated in larger multi-
centre prospective studies.
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